Evidence map›Paper›PMID 26880271›Full record

ArticleNature communications2016

Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway.

Sung Ryeol Park, Ashootosh Tripathi, Jianfeng Wu, Pamela J Schultz, Isaiah Yim, Thomas J McQuade, Fengan Yu, Carl-Johan Arevang, Abraham Y Mensah, Giselle Tamayo-Castillo and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Effects of theBiofilm · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Identification of four novelInternational journal of systematic and evolutionary microbiology · 2025
    Article
  10. mBio · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Role of Antimicrobial Drug in the Development of Potential Therapeutics.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sung Ryeol ParkLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Ashootosh TripathiLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.ORCID http://orcid.org/0000-0003-2297-8088
Jianfeng WuDepartment of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA.
Pamela J SchultzLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Isaiah YimLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Thomas J McQuadeLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Fengan YuLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Carl-Johan ArevangLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Abraham Y MensahLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Giselle Tamayo-CastilloUnidad Estratégica de Bioprospección, Instituto Nacional de Biodiversidad (INBio), Santo Domingo de Heredia 223100, Costa Rica.
Chuanwu XiDepartment of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA.
David H ShermanLife Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI NIZET, VICTOR · 2003 to 2013
$87.6M
of Natural Product based Drugs and Bioenergetic Materials from Costa Rican BiotaU01TW007404 · FIC · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHERMAN, DAVID H · 2005 to 2013
$7.6M
Extracellular ATP in biofilm formation and wound infectionR01GM098350 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XI, CHUANWU · 2011 to 2015
$1.4M
FIC NIH HHS U01 TW007404NIAID NIH HHS U54 AI057153NIAID NIH HHS U54 AI57153NIGMS NIH HHS 1R01GM098350NIGMS NIH HHS R01 GM098350
6 · The paper itself

Abstract

Pathogenic microorganisms often have the ability to attach to a surface, building a complex matrix where they colonize to form a biofilm. This cellular superstructure can display increased resistance to antibiotics and cause serious, persistent health problems in humans. Here we describe a high-throughput in vitro screen to identify inhibitors of Acinetobacter baumannii biofilms using a library of natural product extracts derived from marine microbes. Analysis of extracts derived from Streptomyces gandocaensis results in the discovery of three peptidic metabolites (cahuitamycins A-C), with cahuitamycin C being the most effective inhibitor (IC50=14.5 μM). Biosynthesis of cahuitamycin C proceeds via a convergent biosynthetic pathway, with one of the steps apparently being catalysed by an unlinked gene encoding a 6-methylsalicylate synthase. Efforts to assess starter unit diversification through selective mutasynthesis lead to production of unnatural analogues cahuitamycins D and E of increased potency (IC50=8.4 and 10.5 μM).

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacterial ProteinsBiofilmsBiosynthetic PathwaysHigh-Throughput Screening AssaysOligopeptidesStreptomycesAnti-Bacterial AgentsBacterial Proteinscahuitamycin A protein, Streptomyces gandocaensiscahuitamycin B protein, Streptomyces gandocaensiscahuitamycin C protein, Streptomyces gandocaensisOligopeptides

Identifiers

PMID26880271
PMCPMC4757757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.